Wegovy, a drug for the treatment of obesity manufactured by pharmaceutical company Novo Nordisk, demonstrated positive results in young children in a new clinical study. The drug helped two out of every five participating children lose enough weight to no longer be classified as obese. Currently, Wegovy is approved for use only from the age of 12.
The clinical trial involved children aged over 6 and under 12 years. The majority of participants, 85%, had at the start of the tests a body mass index (BMI) corresponding to a range of severe obesity. After approximately one year of treatment, 40% of the children who received Wegovy were no longer classified as obese.
The participants who received the drug used a weekly injection with a maximum dose of 1.7 mg or 2.4 mg of semaglutide, the active ingredient in Wegovy. The study represents a significant advance in the treatment of childhood obesity, considering that the majority of participating children faced severe cases of obesity.
